Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.
Identifieur interne : 001786 ( PubMed/Corpus ); précédent : 001785; suivant : 001787Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.
Auteurs : Jiaming Lan ; Yao Deng ; Hong Chen ; Guangwen Lu ; Wen Wang ; Xiaojuan Guo ; Zhuozhuang Lu ; George F. Gao ; Wenjie TanSource :
- PloS one [ 1932-6203 ] ; 2014.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Animals, Antigens, Viral (immunology), Drug Delivery Systems (methods), Immunity, Cellular, Immunity, Humoral, Immunization (methods), Mice, Mice, Inbred BALB C, Middle East Respiratory Syndrome Coronavirus (chemistry), Middle East Respiratory Syndrome Coronavirus (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Viral Vaccines.
- chemical , immunology : Antigens, Viral, Viral Vaccines.
- chemistry : Middle East Respiratory Syndrome Coronavirus.
- immunology : Middle East Respiratory Syndrome Coronavirus.
- methods : Drug Delivery Systems, Immunization.
- Animals, Immunity, Cellular, Immunity, Humoral, Mice, Mice, Inbred BALB C.
Abstract
The development of an effective vaccine is critical for prevention of a Middle East respiratory syndrome coronavirus (MERS-CoV) pandemic. Some studies have indicated the receptor-binding domain (RBD) protein of MERS-CoV spike (S) is a good candidate antigen for a MERS-CoV subunit vaccine. However, highly purified proteins are typically not inherently immunogenic. We hypothesised that humoral and cell-mediated immunity would be improved with a modification of the vaccination regimen. Therefore, the immunogenicity of a novel MERS-CoV RBD-based subunit vaccine was tested in mice using different adjuvant formulations and delivery routes. Different vaccination regimens were compared in BALB/c mice immunized 3 times intramuscularly (i.m.) with a vaccine containing 10 µg of recombinant MERS-CoV RBD in combination with either aluminium hydroxide (alum) alone, alum and polyriboinosinic acid (poly I:C) or alum and cysteine-phosphate-guanine (CpG) oligodeoxynucleotides (ODN). The immune responses of mice vaccinated with RBD, incomplete Freund's adjuvant (IFA) and CpG ODN by a subcutaneous (s.c.) route were also investigated. We evaluated the induction of RBD-specific humoral immunity (total IgG and neutralizing antibodies) and cellular immunity (ELISpot assay for IFN-γ spot-forming cells and splenocyte cytokine production). Our findings indicated that the combination of alum and CpG ODN optimized the development of RBD-specific humoral and cellular immunity following subunit vaccination. Interestingly, robust RBD-specific antibody and T-cell responses were induced in mice immunized with the rRBD protein in combination with IFA and CpG ODN, but low level of neutralizing antibodies were elicited. Our data suggest that murine immunity following subunit vaccination can be tailored using adjuvant combinations and delivery routes. The vaccination regimen used in this study is promising and could improve the protection offered by the MERS-CoV subunit vaccine by eliciting effective humoral and cellular immune responses.
DOI: 10.1371/journal.pone.0112602
PubMed: 25405618
Links to Exploration step
pubmed:25405618Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.</title><author><name sortKey="Lan, Jiaming" sort="Lan, Jiaming" uniqKey="Lan J" first="Jiaming" last="Lan">Jiaming Lan</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China; Department of Pathogenic Biology, Hebei Medical University, Shijiazhuang 050017, China.</nlm:affiliation></affiliation></author><author><name sortKey="Deng, Yao" sort="Deng, Yao" uniqKey="Deng Y" first="Yao" last="Deng">Yao Deng</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</nlm:affiliation></affiliation></author><author><name sortKey="Chen, Hong" sort="Chen, Hong" uniqKey="Chen H" first="Hong" last="Chen">Hong Chen</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</nlm:affiliation></affiliation></author><author><name sortKey="Lu, Guangwen" sort="Lu, Guangwen" uniqKey="Lu G" first="Guangwen" last="Lu">Guangwen Lu</name><affiliation><nlm:affiliation>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Wen" sort="Wang, Wen" uniqKey="Wang W" first="Wen" last="Wang">Wen Wang</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</nlm:affiliation></affiliation></author><author><name sortKey="Guo, Xiaojuan" sort="Guo, Xiaojuan" uniqKey="Guo X" first="Xiaojuan" last="Guo">Xiaojuan Guo</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</nlm:affiliation></affiliation></author><author><name sortKey="Lu, Zhuozhuang" sort="Lu, Zhuozhuang" uniqKey="Lu Z" first="Zhuozhuang" last="Lu">Zhuozhuang Lu</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</nlm:affiliation></affiliation></author><author><name sortKey="Gao, George F" sort="Gao, George F" uniqKey="Gao G" first="George F" last="Gao">George F. Gao</name><affiliation><nlm:affiliation>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.</nlm:affiliation></affiliation></author><author><name sortKey="Tan, Wenjie" sort="Tan, Wenjie" uniqKey="Tan W" first="Wenjie" last="Tan">Wenjie Tan</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25405618</idno><idno type="pmid">25405618</idno><idno type="doi">10.1371/journal.pone.0112602</idno><idno type="wicri:Area/PubMed/Corpus">001786</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001786</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.</title><author><name sortKey="Lan, Jiaming" sort="Lan, Jiaming" uniqKey="Lan J" first="Jiaming" last="Lan">Jiaming Lan</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China; Department of Pathogenic Biology, Hebei Medical University, Shijiazhuang 050017, China.</nlm:affiliation></affiliation></author><author><name sortKey="Deng, Yao" sort="Deng, Yao" uniqKey="Deng Y" first="Yao" last="Deng">Yao Deng</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</nlm:affiliation></affiliation></author><author><name sortKey="Chen, Hong" sort="Chen, Hong" uniqKey="Chen H" first="Hong" last="Chen">Hong Chen</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</nlm:affiliation></affiliation></author><author><name sortKey="Lu, Guangwen" sort="Lu, Guangwen" uniqKey="Lu G" first="Guangwen" last="Lu">Guangwen Lu</name><affiliation><nlm:affiliation>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Wen" sort="Wang, Wen" uniqKey="Wang W" first="Wen" last="Wang">Wen Wang</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</nlm:affiliation></affiliation></author><author><name sortKey="Guo, Xiaojuan" sort="Guo, Xiaojuan" uniqKey="Guo X" first="Xiaojuan" last="Guo">Xiaojuan Guo</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</nlm:affiliation></affiliation></author><author><name sortKey="Lu, Zhuozhuang" sort="Lu, Zhuozhuang" uniqKey="Lu Z" first="Zhuozhuang" last="Lu">Zhuozhuang Lu</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</nlm:affiliation></affiliation></author><author><name sortKey="Gao, George F" sort="Gao, George F" uniqKey="Gao G" first="George F" last="Gao">George F. Gao</name><affiliation><nlm:affiliation>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.</nlm:affiliation></affiliation></author><author><name sortKey="Tan, Wenjie" sort="Tan, Wenjie" uniqKey="Tan W" first="Wenjie" last="Tan">Wenjie Tan</name><affiliation><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</nlm:affiliation></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Animals</term><term>Antigens, Viral (immunology)</term><term>Drug Delivery Systems (methods)</term><term>Immunity, Cellular</term><term>Immunity, Humoral</term><term>Immunization (methods)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Middle East Respiratory Syndrome Coronavirus (chemistry)</term><term>Middle East Respiratory Syndrome Coronavirus (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Delivery Systems</term><term>Immunization</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Immunity, Cellular</term><term>Immunity, Humoral</term><term>Mice</term><term>Mice, Inbred BALB C</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The development of an effective vaccine is critical for prevention of a Middle East respiratory syndrome coronavirus (MERS-CoV) pandemic. Some studies have indicated the receptor-binding domain (RBD) protein of MERS-CoV spike (S) is a good candidate antigen for a MERS-CoV subunit vaccine. However, highly purified proteins are typically not inherently immunogenic. We hypothesised that humoral and cell-mediated immunity would be improved with a modification of the vaccination regimen. Therefore, the immunogenicity of a novel MERS-CoV RBD-based subunit vaccine was tested in mice using different adjuvant formulations and delivery routes. Different vaccination regimens were compared in BALB/c mice immunized 3 times intramuscularly (i.m.) with a vaccine containing 10 µg of recombinant MERS-CoV RBD in combination with either aluminium hydroxide (alum) alone, alum and polyriboinosinic acid (poly I:C) or alum and cysteine-phosphate-guanine (CpG) oligodeoxynucleotides (ODN). The immune responses of mice vaccinated with RBD, incomplete Freund's adjuvant (IFA) and CpG ODN by a subcutaneous (s.c.) route were also investigated. We evaluated the induction of RBD-specific humoral immunity (total IgG and neutralizing antibodies) and cellular immunity (ELISpot assay for IFN-γ spot-forming cells and splenocyte cytokine production). Our findings indicated that the combination of alum and CpG ODN optimized the development of RBD-specific humoral and cellular immunity following subunit vaccination. Interestingly, robust RBD-specific antibody and T-cell responses were induced in mice immunized with the rRBD protein in combination with IFA and CpG ODN, but low level of neutralizing antibodies were elicited. Our data suggest that murine immunity following subunit vaccination can be tailored using adjuvant combinations and delivery routes. The vaccination regimen used in this study is promising and could improve the protection offered by the MERS-CoV subunit vaccine by eliciting effective humoral and cellular immune responses. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25405618</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.</ArticleTitle><Pagination><MedlinePgn>e112602</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0112602</ELocationID><Abstract><AbstractText>The development of an effective vaccine is critical for prevention of a Middle East respiratory syndrome coronavirus (MERS-CoV) pandemic. Some studies have indicated the receptor-binding domain (RBD) protein of MERS-CoV spike (S) is a good candidate antigen for a MERS-CoV subunit vaccine. However, highly purified proteins are typically not inherently immunogenic. We hypothesised that humoral and cell-mediated immunity would be improved with a modification of the vaccination regimen. Therefore, the immunogenicity of a novel MERS-CoV RBD-based subunit vaccine was tested in mice using different adjuvant formulations and delivery routes. Different vaccination regimens were compared in BALB/c mice immunized 3 times intramuscularly (i.m.) with a vaccine containing 10 µg of recombinant MERS-CoV RBD in combination with either aluminium hydroxide (alum) alone, alum and polyriboinosinic acid (poly I:C) or alum and cysteine-phosphate-guanine (CpG) oligodeoxynucleotides (ODN). The immune responses of mice vaccinated with RBD, incomplete Freund's adjuvant (IFA) and CpG ODN by a subcutaneous (s.c.) route were also investigated. We evaluated the induction of RBD-specific humoral immunity (total IgG and neutralizing antibodies) and cellular immunity (ELISpot assay for IFN-γ spot-forming cells and splenocyte cytokine production). Our findings indicated that the combination of alum and CpG ODN optimized the development of RBD-specific humoral and cellular immunity following subunit vaccination. Interestingly, robust RBD-specific antibody and T-cell responses were induced in mice immunized with the rRBD protein in combination with IFA and CpG ODN, but low level of neutralizing antibodies were elicited. Our data suggest that murine immunity following subunit vaccination can be tailored using adjuvant combinations and delivery routes. The vaccination regimen used in this study is promising and could improve the protection offered by the MERS-CoV subunit vaccine by eliciting effective humoral and cellular immune responses. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Jiaming</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China; Department of Pathogenic Biology, Hebei Medical University, Shijiazhuang 050017, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Guangwen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xiaojuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Zhuozhuang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>George F</ForeName><Initials>GF</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="Y">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="Y">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>07</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25405618</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0112602</ArticleId><ArticleId IdType="pii">PONE-D-14-33326</ArticleId><ArticleId IdType="pmc">PMC4236105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Infect Immun. 2002 Feb;70(2):584-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11796586</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2014;5(4):e01430-14</Citation><ArticleIdList><ArticleId IdType="pubmed">25006231</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2014;19(23). pii: 20829</Citation><ArticleIdList><ArticleId IdType="pubmed">24957745</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Aug;87(15):8638-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23720729</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Sep;87(17):9939-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23824801</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(7):e69127</Citation><ArticleIdList><ArticleId IdType="pubmed">23844250</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2009 Aug 1;200(3):337-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19569965</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Feb 13;26(7):907-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18201806</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(12):e81587</Citation><ArticleIdList><ArticleId IdType="pubmed">24324708</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2012 Dec;11(12):1405-13</Citation><ArticleIdList><ArticleId IdType="pubmed">23252385</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2014 Apr 11;32(18):2100-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24560617</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Aug 8;500(7461):227-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23831647</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infus Nurs. 2012 May-Jun;35(3):154-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22498485</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2011 Apr;10(4):539-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21506650</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2014 Jun 26;370(26):2499-505</Citation><ArticleIdList><ArticleId IdType="pubmed">24896817</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2013;10:266</Citation><ArticleIdList><ArticleId IdType="pubmed">23978242</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2014 Mar;35(8):2529-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24382332</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2004 Aug 15;173(4):2578-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15294974</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(5):e37019</Citation><ArticleIdList><ArticleId IdType="pubmed">22615877</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Dis. 2013 Aug;5 Suppl 2:S142-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23977435</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Aug 31;28 Suppl 3:C25-36</Citation><ArticleIdList><ArticleId IdType="pubmed">20713254</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Apr 12;29(17):3341-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20713100</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Immunol. 2003 Apr;15(4):505-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12663680</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Apr 18;368(16):1560-2</Citation><ArticleIdList><ArticleId IdType="pubmed">23550601</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(1):e54126</Citation><ArticleIdList><ArticleId IdType="pubmed">23335993</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2012 Dec;65(6):477-89</Citation><ArticleIdList><ArticleId IdType="pubmed">23072791</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Dec 14;30(52):7498-505</Citation><ArticleIdList><ArticleId IdType="pubmed">23116697</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2009 Apr;5(4):e1000373</Citation><ArticleIdList><ArticleId IdType="pubmed">19360120</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2013 Jul 31;4:214</Citation><ArticleIdList><ArticleId IdType="pubmed">23914187</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Immunol. 2014 Jun;28:1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24463269</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbes Infect. 2013 Jul-Aug;15(8-9):625-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23791956</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Aug;87(16):9379-83</Citation><ArticleIdList><ArticleId IdType="pubmed">23785207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001786 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001786 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25405618
|texte= Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25405618" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |